EscudierB.: Advanced renal cell carcinoma: current and emerging management strategies. Drugs, 67: 1257–1264, 2007.
2.
OudardS., GorgeD., MedioniJ., MotzerR.: Treatment options in renal cell carcinoma: past, present and future. Ann Oncol, 18(Suppl 10): x25–31, 2007.
3.
IesalnieksI., WoenckhausM., GlockzinG., SchlittH.J., AghaA.: Renal cell carcinoma metastases to the thyroid gland-report of 3 cases and review of the literature. Zentralbl Chir, 131: 235–239, 2006.
4.
MayM., MaruschF., KaufmannO., SeehaferM., HelkeC., HoschkeB., GastingerI.: Solitary renal cell carcinoma metastasis to the thyroid gland: a paradigm of metastasectomy?Chirurg, 74: 768–774, 2003.
5.
RatainM.J., EisenT., StadlerW.M., FlahertyK.T., KayeS.B., RosnerG.L., GoreM., DesaiA.A., PatnaikA., XiongH.Q., RowinskyE., AbruzzeseJ.L., XiaC., SimantovR., SchwartzB., O'DwyerP.J.: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol, 24: 2505–2512, 2006.
6.
SonpavdeG., HutsonT.E.: Recent advances in the therapy of renal cancer. Expert Opin Biol Ther, 7: 233–242, 2007.
7.
HutsonT.E., FiglinR.A.: Evolving role of novel targeted agents in renal cell carcinoma. Oncology (Williston Park), 21: 1175–1180, 2007.
8.
GrandinettiC.A., GoldspielB.R.: Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy, 27: 1125–1144, 2007.
